Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that the U.S. Food and Drug Administration (FDA) has extended its review timeline of the Biologics License Application (BLA) seeking accelerated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback